HUMENAS®

REG. SAN. NO. INVIMA:
INVIMA 2020M-0013606-R1

PRINCIPIO ACTIVO:
Solucion Salina.

UNIDAD DE VENTA:
0,65 G / 100 mL

HUMENAS® GL

Reg. San. No. INVIMA:

INVIMA 2018M-0018545

Principio activo:

Humectante nasal.

Unidad de Venta:

30 mL

DESLODEX®

REGISTRO SANITARIO:
INVIMA 2020M-0007347-R1

COMPOSICIÓN:
Desloratadina 2,5 mg/5 mL

ACIDRINE®

REG. SAN. NO. INVIMA:
INVIMA 2009M-0009888

PRINCIPIO ACTIVO:
Cetirizina Diclorhidrato 5mg/5mL

UNIDAD DE VENTA:
Jarabe

OLONASE®

Reg. San. No. INVIMA: INVIMA 2018M-0018484
PRINCIPIO ACTIVO: Olopatadina 0.6%
UNIDAD DE VENTA: Spray Nasal Solucion.

AZEFLU®

REGISTRO SANITARIO:
INVIMA 2018M-0018440

PRINCIPIO ACTIVO:
Azelastina Clorhidrato 137 mcg-Fluticasona Propionato 50 mcg.

UNIDAD DE VENTA:
Suspension Spray Nasal

METASPRAY®

REG. SAN. NO. INVIMA:
INVIMA 2020M-0014173-R1

PRINCIPIO ACTIVO:
Furoato de mometasona 50 mcg

UNIDAD DE VENTA:
Suspension para Inhalación Nasal

AIROMED®

REG. SAN. NO. INVIMA:
INVIMA 2020M-0014289-R1

PRINCIPIO ACTIVO:
Montelukast 5mg

UNIDAD DE VENTA:
Caja por 30 tabletas masticables

 

DESLODEX® DUO

REG. SAN. NO. INVIMA:
INVIMA 2018M-0018531

PRINCIPIO ACTIVO:
Desloratadina 5mg + Montelukast 10 mg

UNIDAD DE VENTA:
Tabletas recubiertas

 

PEPRED®

REGISTRO SANITARIO:
INVIMA 2012M-0012798

PRINCIPIO ACTIVO:
Prednisolona 1mg/mL

PRESENTACIÓN:
Solucion

PRECORT®

REGISTRO SANITARIO:
INVIMA 2019M-0019069

PRINCIPIO ACTIVO:

Metilprednisolona

UNIDAD DE VENTA:
Tabletas Recubiertas

Bibliografía recomendada:

    1. Scadding GK, Smith PK, Blaiss M, Roberts G, Hellings PW, Gevaert P, et al. Allergic Rhinitis in Childhood and the New EUFOREA Algorithm. Front Allergy (2021)
    2. Leger D, Bonnefoy B, Pigearias B, de La Giclais B, Chartier A. Poor sleep is highly associated with house dust mite allergic rhinitis in adults and children. Allergy Asthma Clin Immunol.(2017)
    3. Cingi C, Gevaert P, Mösges R, Rondon C, Hox V, Hupin C, et al.. Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology Task Force Report. Clin Transl Allergy. (2017)
    4. Blaiss MS, Hammerby E, Robinson S, Kennedy-Martin T, Buchs S. The burden of allergic rhinitis and allergic rhinoconjunctivitis on adolescents: a literature review. Ann Allergy Asthma Immunol.(2018)
    5. Shaaban R, Zureik M, Soussan D, Neukirch C, Heinrich J, Sunyer J, et al.. Rhinitis and onset of asthma: a longitudinal population-based study. (2008)
    6. Scadding GK, Hellings PW, Bachert C, Bjermer L, Diamant Z Gevaert P, et al.. Allergic respiratory disease care in the COVID-19 era: a EUFOREA statement. World Allergy Organ J.(2020)
    7. Prokopakis E, Vardouniotis A, Bachert C, Bousquet J, Carrie S, Castelnuevo P, et al.. Rhinology future debates 2018, a EUFOREA report. (2020)
    8. Hellings PW, Scadding GK, Bachert C, Bjermer L, Canonica GW, Cardell LO, et al.. EUFOREA treatment algorithm for allergic rhinitis. (2020)
    9. Scadding GK, Kariyawasam HH, Scadding G, Mirakian R, Buckley RJ, Dixon T, et al.. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (revised edition 2017; first edition 2007). Clin Exp Allergy.(2017)
    10. Roberts G, Xatzipsalti M, Borrego LM, Custovic A, Halken S, Hellings PW, et al.. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. (2013)
    11. Bousquet J, Schünemann HJ, Togias A, Bachert C, Erhola M, Hellings PW, et al.. Next- generation allergic rhinitis and its impact on asthma (ARIA) guidelines for allergic rhinitis based on grading of recommendations, assessment, development and evaluation (GRADE)and real- world evidence.  Allergy Clin Immunol.(2020)
    12. Dykewicz MS, Wallace DV, Amrol DJ, Baroody FM, Bernstein JA, Craig TJ, et al.. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol.(2020)
    13. Aït-Khaled N, Pearce N, Anderson HR, Ellwood P, Montefort S, Shah J, et al.. Global map of the prevalence of symptoms of rhinoconjunctivitis in children: the international study of asthma and allergies in childhood (ISAAC) phase three. (2009)
    14. Kim DH, Lim DH, Samra M, Kim EH, Kim JH. How accurate are the ISAAC questions for diagnosis of allergic rhinitis in Korean children? Int J Environ Res Public Health.(2018)
    15. Scadding GK, Scadding GW. Innate and adaptive immunity: ILC2 and Th2 cells in upper and lower airway allergic diseases. J Allergy Clin Immunol Pract.(2021)
    16. Gough H, Grabenhenrich L, Reich A, Eckers N, Nitsche O, Schramm D, et al.. Allergic multimorbidity of asthma, rhinitis and eczema over 20 years in the German birth cohort MAS. Pediatr Allergy Immunol.(2015)
    17. Grabenhenrich LB, Keil T, Reich A, Gough H, Beschorner J, Hoffmann U, et al.. Prediction and prevention of allergic rhinitis: a birth cohort study of 20 years. J Allergy Clin Immunol.(2015)
    18. Williams DC, Edney G, Maiden B, Smith PK. Recognition of allergic conjunctivitis in patients with allergic rhinitis. World Allergy Organ J.(2013) 6:4. 10.1186/1939-4551-6-4 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
    19. Keller T, Hohmann C, Standl M, Wijga AH, Gehring U, Melén E, et al.. The sex-shift in single disease and multimorbid asthma and rhinitis during puberty – a study by MeDALL. (2018)
    20. Wahn U, Keil T, Grabenhenrich L. The development of allergic rhinitis in childhood. In: Sampson HA, Wahn U, editors. Allergy, Immunity and Tolerance in Early Childhood. Academic Press; (2016)
    21. Rotiroti G, Roberts G, Scadding GK. Rhinitis in children: common clinical presentations and differential diagnoses. Pediatr Allergy Immunol.(2015)
    22. Greiner AN, Hellings PW, Rotiroti G, Scadding GK. Allergic rhinitis. (2011)
    23. Scadding GK, Hellings P, Alobid I, Bachert C, Fokkens W, van Wijk RG, et al.. Diagnostic tools in rhinology EAACI position paper. Clin Trans Allergy.(2011)
    24. Cipriani F, Tripodi S, Panetta V, Perna S, Potapova E, Dondi A, et al.. Early molecular biomarkers predicting the evolution of allergic rhinitis and its comorbidities: a longitudinal multicenter study of a patient cohort. Pediatr Allergy Immunol.(2019)
    25. Steering Committee Authors and Review Panel Members . A WAO – ARIA – GA2LEN consensus document on molecular- based allergy diagnosis (PAMD@): update 2020. World Allergy Organ J. (2020)
    26. Westman M, Åberg K, Apostolovic D, Lupinek C, Gattinger P, Mittermann I, et al.. Sensitization to grass pollen allergen molecules in a birth cohort-natural Phl p 4 as an early indicator of grass pollen allergy. J Allergy Clin Immunol.(2020)
    27. Scadding G K. Optimal management of allergic rhinitis. Arch Dis Child.(2015)
    28. Berger W, Meltzer EO, Amar N, Fox AT, Just J, Muraro A, et al.. Efficacy of AzeFlu in children with seasonal allergic rhinitis: importance of paediatric symptom assessment. Pediatr Allergy Immunol.(2016)
    29. Hermelingmeier KE, Weber RK, Hellmich M, Heubach CP, Mosges R. Nasal irrigation as anadjunctive treatment in allergic rhinitis: a systematic review and meta- analysis. Am J Rhinol Allergy.(2012)
    30. Head K, Snidvongs K, Glew S, Scadding G, Schilder AGM, Philpott C, et al.. Saline irrigation for allergic rhinitis. Cochrane Database Syst Rev.(2018)
    31. Kawauchi H, Yanai K, Wang DY, Itahashi K, Okubo K. Antihistamines for allergic rhinitis treatment from the viewpoint of nonsedative properties. Int J Mol Sci.(2019)
    32. Meltzer EO, Blaiss M, Fairchild CJ. Comprehensive report of olopatadine 0.6% nasal spray as treatment for children with seasonal allergic rhinitis. Allergy Asthma Proc.(2011)
    33. Shah SR, Nayak A, Ratner P, Roland P, Michael Wall G. Effects of olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: a phase III, multicenter, randomized, double-blind, active- and placebo-controlled study in adolescents and adults. Clin Ther.(2009)
    34. Wallace DV, Dykewicz MS. Comparing the evidence in allergic rhinitis guidelines. Curr Opin Allergy Clin Immunol.(2017)
    35. Blaiss MS. Safety update regarding intranasal corticosteroids for the treatment of allergic rhinitis. Allergy Asthma Proc.(2011)
    36. Brozek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S. Allergic rhinitis and its impact on asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol.(2017)
    37. Wallace DV, Dykewicz MS, Oppenheimer J, Portnoy JM, Lang DM. Pharmacologic treatment of seasonal allergic rhinitis: synopsis of guidance from the 2017 joint task force on practice parameters. Intern Med.(2017)
    38. Zhao M, Li H, Li H. The relevance of CYSLTR1 gene polymorphism to the severity of allergic rhinitis and clinical responsiveness of montelukast in children. Eur Arch Otorhinolaryngol.(2021).
    39. Scadding GW, Scadding GK. Recent advances in antileukotriene therapy. Curr Opin Allergy Clin Immunol.(2010)
    40. Wallerstedt SM, Brunlöf G, Sundström A, Eriksson AL. Montelukast and psychiatric disorders in children. Pharmacoepidemiol Drug Saf.(2009)
    41. Venter C, Greenhawt M, Meyer RW, Agostoni C, Reese I, du Toit G, et al.. EAACI position paper on diet diversity in pregnancy, infancy and childhood: novel concepts and implications for studies in allergy and asthma. (2020)